|
MechanismAKR1B1 inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy
This clinical trial is to determine an effective dosage and to study the safety of an investigational drug -lidorestat (IDD-676)- which is intended to stop or slow the progression of diabetic peripheral neuropathy.
100 Clinical Results associated with The Institute For Diabetes Discovery Llc
0 Patents (Medical) associated with The Institute For Diabetes Discovery Llc
100 Deals associated with The Institute For Diabetes Discovery Llc
100 Translational Medicine associated with The Institute For Diabetes Discovery Llc